Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma

Cancer

Volumn 88, Issue 2, 2000, Pages 389-397

  Scarabelli, Carlo ^a,d   Gallo, Angelo ^a   Franceschi, Silvia ^b   Campagnutta, Elio ^a   De Piero, Giovanni ^a   Giorda, Giorgio ^a   Visentin, Maria Caterina ^a   Carbone, Antonino ^c  

^a Division of Medical Oncology   (Italy)

^b Ist Naz Ricovero Cura Carattere S   (Italy)

^c Division of Pathology   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Bowel surgery; Cytoreductive surgery; Ovarian carcinoma; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; SIGMOIDECTOMY; SURGICAL TECHNIQUE;

ADULT; AGED; CARCINOMA; COLON, SIGMOID; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0034650684     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000115)88:2<389::AID-CNCR21>3.0.CO;2-W     Document Type: Article

References (37)

1. Griffiths CT, Parker LM, Fuller AF Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235-40.
2. Hacker NF, Berek JS, Lagasse CD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.
3. Delgado G, Oram DH, Petril ES. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 1984;18:293-8.
4. Piver MS, Lele SB, Marchetti DL, Baker TR, Tsukado Y, Emrich LJ. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in Stage III and IV ovarian carcinoma. J Clin Oncol 1988;6: 983-9.
5. Vogl SE, Pagano M, Kaplan BH, Greenwald E, Arsenau J, Bennett B. Cisplatin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potential only in women with small tumor burdens. Cancer 1983;51:2024-30.
6. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, Willemse PH, Vermorken JB, et al. Long term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991;27:1367-72.
7. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989;7:457-65.
8. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM. Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991;40:195-20.
9. Guidozzi F, Ball JHS. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994;53:326-30.
10. Berek JS, Hacker NF, Lagasse LD. Rectosigmoid colectomy and reanastomosis to facilitate resection of primary and recurrent gynecologic cancer. Obstet Gynecol 1984;64:715-20.
11. Chassin JL. Operations for rectal cancer. In: Operative strategy in general surgery. vol I. New York: Springer-Verlag, 1980:335-77.
12. American Joint Committee on Cancer. Manual for staging of cancer. 4th ed. Philadelphia: J.B. Lippincott Company, 1992.
13. Scarabelli C, Gallo A, Visentin MC, Canzonieri V, Carbone A, Zarrelli A. Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer 1997;7:18-26.
14. Scarabelli C, Gallo A, Campagnutta E, Carbone A. Splenectomy during primary and secondary cytoreductive surgery for epithelial ovarian carcinoma. Int J Gynecol Cancer 1998; 8:215-21.
15. Soper JT, Couchman G, Berchuck A, Clarke-Pearson D. The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol 1991;41:239-44.
16. Dixon CF. Anterior resection for carcinoma low in the sigmoid and rectosigmoid. Surgery 1944;15:367-75.
17. Ravitch MM, Steichen FM. A stapling instrument for end-to-end inverting anastomoses in the gastrointestinal tract. Ann Surg 1979;189:791-800.
18. Wheeless CR. Avoidance of permanent colostomy in pelvic malignancy using the surgical stapler. Obstet Gynecol 1979; 54:501-9.
19. Hatch KD, Shingleton HM, Soong SJ, Baker VV, Gelder MS. Anterior pelvic exenteration. Gynecol Oncol 1988;31:205-13.
20. World Health Organization. WHO handbook for reporting results of cancer treatments. World Health Organization offset publication no. 48. Geneva: World Health Organization, 1979.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
23. Cox DR. Regression models and life tables. J R Stat Soc B 1972;33:187-220.
24. Heintz APM, Hacker NF, Berek JS, Rase TP, Munoz AK, Lagasse LD. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986;67:783-8.
25. Jänicke F, Hölscher M, Kuhn W, von Hugo R, Pache L, Siewert JR, et al. radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129-36.
26. Kuhn W, Florack G, Roder J, Schmalfeldt B, Pache L, Rust M, et al. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. Int J Gynecol Cancer 1998;8:56-63.
27. Brunschwig AD. Complete excision of pelvic viscera for advanced carcinoma. Cancer 1948;1:177-83.
28. Kalinina TV. The use of the apparatus PKS25 and SK in the clinic. In: Mechanical sutures in surgery of the gastrointestinal tract. Moscow, 1964.
29. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994;55:401-9.
30. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancer. Int J Cancer (Pred Oncol) 1997;74:193-8.
31. Toffoli G, Russo A, Gallo A, Cernigoi C, Miotti S, Sorio R, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer (Pred Oncol) 1998;79:121-6.
32. Van der Burg MEL, Van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-34.
33. Girling JC, Souter WP. Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: a topic for debate. Int J Gynecol Cancer 1996;6:81-4.
34. Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. Gynecol Oncol 1995;56:328-37.
35. Lax SF, Petru E, Holzer E, Pertl AM, Ralph G, Greenspan DL, et al. Mesenteric and mesocolic lymph node metastases from ovarian carcinoma: a clinicopathological analysis. Int J Gynecol Cancer 1998;8:119-23.
36. O'Hanlan KA, Kargas S, Schreiber M, Burrs D, Mallipeddi P, Longacre T, et al. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol 1995;59: 200-6.
37. Bouwman DL, Weaver DW. Colon cancer: surgical therapy. Gastroenterol Clin North Am 1988;17:859-72.